The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2019 | Approval of Dvd for myeloma at first relapse in the UK: impacts on care
Tanya Burton
• 2 Apr 2019
Tanya Burton, University Hospital of Wales, Cardiff, UK, discusses the recent approval of daratumumab with bortezomib and dexamethasone for multiple myeloma at first relapse in the UK. She highlights how this will impact both patient care and day units. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK,
